SG165162A1 - Modified release pharmaceutical formulation - Google Patents

Modified release pharmaceutical formulation

Info

Publication number
SG165162A1
SG165162A1 SG200608336-4A SG2006083364A SG165162A1 SG 165162 A1 SG165162 A1 SG 165162A1 SG 2006083364 A SG2006083364 A SG 2006083364A SG 165162 A1 SG165162 A1 SG 165162A1
Authority
SG
Singapore
Prior art keywords
modified release
release pharmaceutical
pharmaceutical formulation
formulation
carragaenan
Prior art date
Application number
SG200608336-4A
Other languages
English (en)
Inventor
Anders Magnusson
Mikael Thune
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG165162A1 publication Critical patent/SG165162A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200608336-4A 2002-05-31 2003-05-27 Modified release pharmaceutical formulation SG165162A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201659A SE0201659D0 (sv) 2002-05-31 2002-05-31 Modified release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SG165162A1 true SG165162A1 (en) 2010-10-28

Family

ID=20288037

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200608336-4A SG165162A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation

Country Status (23)

Country Link
US (1) US7202236B2 (fr)
EP (1) EP1513495A1 (fr)
JP (2) JP4603353B2 (fr)
KR (1) KR101166921B1 (fr)
CN (2) CN101264051B (fr)
AR (1) AR039936A1 (fr)
AU (2) AU2003232870B2 (fr)
BR (1) BR0311460A (fr)
CA (1) CA2485535C (fr)
EG (1) EG24479A (fr)
IL (1) IL165029A0 (fr)
IS (1) IS7564A (fr)
MX (1) MXPA04011914A (fr)
NO (1) NO20044767L (fr)
NZ (1) NZ536621A (fr)
PL (1) PL374299A1 (fr)
RU (2) RU2474416C2 (fr)
SA (1) SA03240402B1 (fr)
SE (1) SE0201659D0 (fr)
SG (1) SG165162A1 (fr)
TW (2) TWI319317B (fr)
WO (1) WO2003101424A1 (fr)
ZA (1) ZA200409234B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
JP5006800B2 (ja) 2005-01-17 2012-08-22 ユィロス・パテント・アクチボラグ 二つの親和性反応物を用いて、少なくとも二価のアナライトを検出する方法
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
WO2009002817A1 (fr) * 2007-06-25 2008-12-31 Cp Kelco U.S., Inc. Carraghénine
US20080317789A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
US20080317790A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
US20080317791A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
US20080317927A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
US20080317926A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
US8268808B2 (en) * 2007-06-25 2012-09-18 Cp Kelco U.S., Inc. Carrageenan and carrageenan-containing products
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
US9125434B2 (en) * 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
AU2008311350B2 (en) * 2007-10-11 2014-04-03 Philip Morris Products S.A. Smokeless tobacco product
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
AU2008328584A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US8293285B2 (en) * 2008-03-14 2012-10-23 Cp Kelco U.S., Inc. Carrageenan modified by ion-exchange process
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
EP3512495B1 (fr) * 2016-09-15 2022-11-09 Camurus AB Formulations d'analogues de prostacycline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039770A1 (fr) * 1996-04-24 1997-10-30 Astra Aktiebolag Nouvelle formulation pharmaceutique d'un inhibiteur de la thrombine pour une utilisation parenterale
WO1998016252A1 (fr) * 1996-10-11 1998-04-23 Astra Aktiebolag Novelle formulation pharmaceutique parenterale d'un inhibiteur de thrombine
WO2002019990A1 (fr) * 2000-09-05 2002-03-14 Astrazeneca Ab Formulation a liberation modifiee

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (fr) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de protease HIV
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
TW201303B (fr) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (fr) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Aldehydes peptidiques utilises comme agents antithrombotiques
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
CA2131367A1 (fr) 1992-03-04 1993-09-16 Sandor Bajusz Nouveaux derives peptidiques anticoagulants et compositions pharmaceutiques en contenant; procede de fabrication
TW223629B (fr) 1992-03-06 1994-05-11 Hoffmann La Roche
US5783563A (en) 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (fr) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Inhibiteurs hétérocycliques de thrombine
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (fr) 1994-01-27 2010-03-09 Masahiro Ohshima Derives de la prolineamide
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
SK104697A3 (en) 1995-02-17 1998-11-04 Basf Ag Novel dipeptide amidines as thrombin inhibitors
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
EP0820453A4 (fr) 1995-04-04 2001-08-29 Merck & Co Inc Inhibiteurs de thrombine
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
AU3496297A (en) 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IL141688A0 (en) 1998-09-04 2002-03-10 Scios Inc Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
TR200102037T2 (tr) 1999-01-13 2001-10-22 Astrazeneca Ab Yeni amidinobenzilamin türevleri ve trombin engelleyiciler olarak kullanılmaları.
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
IL154077A0 (en) 2000-08-16 2003-07-31 Astrazeneca Ab New amidino derivatives and their use as thrombin inhibitors
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA78195C2 (uk) 2001-08-30 2007-03-15 Astrazeneca Ab Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039770A1 (fr) * 1996-04-24 1997-10-30 Astra Aktiebolag Nouvelle formulation pharmaceutique d'un inhibiteur de la thrombine pour une utilisation parenterale
WO1998016252A1 (fr) * 1996-10-11 1998-04-23 Astra Aktiebolag Novelle formulation pharmaceutique parenterale d'un inhibiteur de thrombine
WO2002019990A1 (fr) * 2000-09-05 2002-03-14 Astrazeneca Ab Formulation a liberation modifiee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EFFECT OF PH ON DRUG RELEASE FROM POLYSACCHARIDE TABLETS *
ON THE EMPLOYMENT OF A-CARRAGEENAN IN A MATRIX SYSTEM. II.A-CARRAGEENAN AND HYDROXYPROPYLMETHYLCELLULOSE MIXTURES *

Also Published As

Publication number Publication date
JP4603353B2 (ja) 2010-12-22
SE0201659D0 (sv) 2002-05-31
TW200913989A (en) 2009-04-01
CN101264051B (zh) 2010-12-22
JP2009298795A (ja) 2009-12-24
MXPA04011914A (es) 2005-03-31
EG24479A (en) 2009-08-03
IL165029A0 (en) 2005-12-18
TWI319317B (en) 2010-01-11
KR20050010013A (ko) 2005-01-26
SA03240402B1 (ar) 2008-03-23
AR039936A1 (es) 2005-03-09
CN100402025C (zh) 2008-07-16
KR101166921B1 (ko) 2012-07-23
PL374299A1 (en) 2005-10-03
TWI319318B (en) 2010-01-11
EP1513495A1 (fr) 2005-03-16
AU2003232870B2 (en) 2009-09-10
ZA200409234B (en) 2005-07-12
RU2004132856A (ru) 2005-08-10
RU2008142261A (ru) 2010-05-10
CA2485535A1 (fr) 2003-12-11
NO20044767L (no) 2005-02-25
NZ536621A (en) 2006-10-27
WO2003101424A1 (fr) 2003-12-11
RU2352323C2 (ru) 2009-04-20
CN101264051A (zh) 2008-09-17
AU2009243524A1 (en) 2009-12-24
TW200403992A (en) 2004-03-16
BR0311460A (pt) 2005-03-29
AU2003232870A1 (en) 2003-12-19
US7202236B2 (en) 2007-04-10
CN1655761A (zh) 2005-08-17
IS7564A (is) 2004-11-29
CA2485535C (fr) 2011-05-10
JP2005536472A (ja) 2005-12-02
US20050171083A1 (en) 2005-08-04
RU2474416C2 (ru) 2013-02-10

Similar Documents

Publication Publication Date Title
SG165162A1 (en) Modified release pharmaceutical formulation
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
AU2002239344A1 (en) Pyrazolopyridines
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
SE0202463D0 (sv) Novel compounds
AP1739A (en) Azaindoles
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
HK1048990A1 (en) Novel compounds.
AU2003228770A1 (en) Substituted pyrazolopyrimidines
AU2002239348A1 (en) Pyrazolopyridine derivatives
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
SE9903997D0 (sv) New compounds
TW200735864A (en) Immediate release pharmaceutical formulation
GB0109122D0 (en) Novel compounds
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0203070D0 (en) Novel compounds
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2002248531A1 (en) Pyrazolopyriadine derivatives
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.